- Home
- INO vs CTSO Comparison
INO vs CTSO Comparison
Compare INO & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INO
- CTSO
- Stock Information
- Founded
- INO 1979
- CTSO 1997
- Country
- INO United States
- CTSO United States
- Employees
- INO N/A
- CTSO N/A
- Industry
- INO Medical/Dental Instruments
- CTSO Medical/Dental Instruments
- Sector
- INO Health Care
- CTSO Health Care
- Exchange
- INO Nasdaq
- CTSO Nasdaq
- Market Cap
- INO 69.3M
- CTSO 72.8M
- IPO Year
- INO 1998
- CTSO N/A
- Fundamental
- Price
- INO $1.96
- CTSO $0.91
- Analyst Decision
- INO Buy
- CTSO Buy
- Analyst Count
- INO 5
- CTSO 2
- Target Price
- INO $8.80
- CTSO $5.50
- AVG Volume (30 Days)
- INO 1.9M
- CTSO 379.8K
- Earning Date
- INO 08-12-2025
- CTSO 08-07-2025
- Dividend Yield
- INO N/A
- CTSO N/A
- EPS Growth
- INO N/A
- CTSO N/A
- EPS
- INO N/A
- CTSO N/A
- Revenue
- INO $182,337.00
- CTSO $36,107,520.00
- Revenue This Year
- INO N/A
- CTSO $11.15
- Revenue Next Year
- INO $20,588.06
- CTSO $21.39
- P/E Ratio
- INO N/A
- CTSO N/A
- Revenue Growth
- INO N/A
- CTSO 20.18
- 52 Week Low
- INO $1.30
- CTSO $0.71
- 52 Week High
- INO $7.76
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- INO 66.94
- CTSO 44.06
- Support Level
- INO $1.80
- CTSO $0.83
- Resistance Level
- INO $2.08
- CTSO $1.19
- Average True Range (ATR)
- INO 0.12
- CTSO 0.09
- MACD
- INO 0.06
- CTSO -0.01
- Stochastic Oscillator
- INO 82.35
- CTSO 21.91
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.